Literature DB >> 19540647

Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis.

Corine M Koopmans1, Maria G van Pampus, Henk Groen, Jan G Aarnoudse, Paul P van den Berg, Ben W J Mol.   

Abstract

The aim of this study is to determine the accuracy and clinical value of serum uric acid in predicting maternal complications in women with pre-eclampsia. An existing meta-analysis on the subject was updated. The accuracy of serum uric acid for the prediction of maternal complications was assessed with a bivariate model estimating a summary Receiver Operating Characteristic (sROC) curve. Subsequently, a clinical decision analysis was performed, in which three alternative strategies were modelled: (I) expectant management with monitoring until spontaneous labour; (II) induction of labour; (III) serum uric acid as test for predicting maternal complications. In the latter strategy, accuracy data of serum uric acid derived from the sROC curve were used to assess the value of serum uric acid in the management of women with pre-eclampsia. In this strategy, women with an increased serum uric acid were supposed to have labour induced, whereas women with serum uric acid levels below the threshold were managed expectantly. The decision whether to use the policy expectant management, to induce labour or to test serum uric acid levels, is based on the expected utility of each strategy. The expected utility depends on the probability of occurrence of severe maternal complications (i.e. severe hypertension, haemolysis, elevated liver enzymes and low platelet count (HELLP syndrome) or eclampsia) and the mode of delivery (caesarean section versus vaginal delivery). Valuation of the outcomes was performed using a distress ratio, which expresses how much worse a complication of pre-eclampsia is valued as compared to a caesarean section. Eight studies, testing 1565 women with pre-eclampsia, met the inclusion criteria. If the distress ratio was 10, the strategy regarding serum uric acid would be the preferred strategy when the probability of complications was between 2.9 and 6.3%. At higher complication rates induction of labour would be preferred, whereas at lower complication rates expectant management would be the best treatment option. These findings were stable in sensitivity analyses, using different distress ratios. Based on the decision analysis, serum uric acid seems to be a useful test in the management of pre-eclampsia under realistic assumptions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540647     DOI: 10.1016/j.ejogrb.2009.05.014

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  16 in total

1.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

2.  Serum uric acid may not be involved in the development of preeclampsia.

Authors:  Q Chen; S Lau; M Tong; J Wei; F Shen; J Zhao; M Zhao
Journal:  J Hum Hypertens       Date:  2015-05-21       Impact factor: 3.012

3.  Uric acid: is it time to give up routine testing in management of pre-eclampsia?

Authors:  Vikram Sinai Talaulikar; Hassan Shehata
Journal:  Obstet Med       Date:  2012-03-29

4.  Uric acid induces trophoblast IL-1β production via the inflammasome: implications for the pathogenesis of preeclampsia.

Authors:  Melissa J Mulla; Kledia Myrtolli; Julie Potter; Crina Boeras; Paula B Kavathas; Anna K Sfakianaki; Serkelem Tadesse; Errol R Norwitz; Seth Guller; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2011-06       Impact factor: 3.886

Review 5.  Could uric acid have a pathogenic role in pre-eclampsia?

Authors:  Annabel C Martin; Mark A Brown
Journal:  Nat Rev Nephrol       Date:  2010-10-19       Impact factor: 28.314

6.  Serum uric acid levels associated with biochemical parameters linked to preeclampsia severity and to adverse perinatal outcomes.

Authors:  Elaine Luiza Santos Soares de Mendonça; João Victor Farias da Silva; Carolina Santos Mello; Alane Cabral Menezes de Oliveira
Journal:  Arch Gynecol Obstet       Date:  2022-01-07       Impact factor: 2.344

7.  Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Authors:  John V Ilekis; Ekaterini Tsilou; Susan Fisher; Vikki M Abrahams; Michael J Soares; James C Cross; Stacy Zamudio; Nicholas P Illsley; Leslie Myatt; Christine Colvis; Maged M Costantine; David M Haas; Yoel Sadovsky; Carl Weiner; Erik Rytting; Gene Bidwell
Journal:  Am J Obstet Gynecol       Date:  2016-03-10       Impact factor: 8.661

8.  Antepartum or immediate postpartum renal biopsies in preeclampsia/eclampsia of pregnancy: new morphologic and clinical findings.

Authors:  Lei Han; Zhiling Yang; Kailong Li; Jiaqun Zou; Hongmei Li; Jian Han; Lijuan Zhou; Xiaojie Liu; Xin Zhang; Yingru Zheng; Lili Yu; Li Li
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

Review 9.  The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis.

Authors:  Ioannis Bellos; Vasilios Pergialiotis; Dimitrios Loutradis; Georgios Daskalakis
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-04-27       Impact factor: 3.738

Review 10.  A comprehensive review of hypertension in pregnancy.

Authors:  Reem Mustafa; Sana Ahmed; Anu Gupta; Rocco C Venuto
Journal:  J Pregnancy       Date:  2012-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.